Insulin Makers Sanofi, Novo Nordisk & Lilly Named in Price-Fixing Suit

Jan 31, 2017

Sanofi, Novo Nordisk and Eli Lilly have been named in a class action lawsuit that alleges the insulin makers of price fixing.

Filed by a group of patients in a federal court in Massachusetts, the suit accuses the three biggest makers of diabetes treatments of simultaneously raising the price of insulin by more than 150 percent over a five year period and for violating the Racketeer Influenced and Corrupt Organizations Act.

Plaintiffs claim that the companies raised their public benchmark price while maintaining lower prices for large pharmacy benefit managers, which act as middle men with health insurers to keep a percentage of the price difference.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments